Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03220295 · ClinicalTrials.gov registry record · Phase 1
Putative Cognitive Enhancer VU319
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03220295: Completed Phase 1 study, sponsored by Vanderbilt University.
NCT03220295 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 52 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03220295, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.
Primary Outcome
Frequency of adverse events per ascending dose cohort
Interventions
- DRUG Single Dose of VU319
- DRUG Single Dose Placebo
- OTHER Fed State
- OTHER Fasted State
- DRUG Dose Escalation of VU319
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2017-07-28 |
| Est. Completion | 2019-10-30 |
| Phase | Phase 1 |
What the finished NCT03220295 record still lists
NCT03220295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 5 interventions - of which Single Dose of VU319 is the first listed.
NCT03220295 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03220295 about?
NCT03220295 is a clinical study titled "Putative Cognitive Enhancer VU319". This is a safety study of the molecule VU319 to ascertain pharmacokinetic and pharmacodynamic data and test cognitive enhancement in healthy volunteers.
What is the current status of trial NCT03220295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2017-07-28. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT03220295?
The interventions under investigation include: Single Dose of VU319 (DRUG), Single Dose Placebo (DRUG), Fed State (OTHER), Fasted State (OTHER), Dose Escalation of VU319 (DRUG).
Who is sponsoring clinical trial NCT03220295?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03220295's enrollment target sits among peer trials
52 956th of 2000 higher than 1,032 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI